Integrating radiological and clinical data for clinically significant prostate cancer detection with machine learning techniques by Luis Mariano Esteban, Ángel Borque-Fernando, Maria Etelvina Escorihuela, Javier Esteban-Escaño, Jose María Abascal, Pol Servian, Juan Morote

Subjects: “…Clinically significant prostate cancer…”
Get full text

Matrix metalloproteinase-3 is a potent prognostic factor associated with cell proliferation and migration in prostate cancer by Ai Sato, Kiyoshi Takagi, Mio Yamaguchi-Tanaka, Jotaro Okushima, Yuto Yamazaki, Akihiro Ito, Takashi Suzuki

Subjects: Get full text

Causal associations between socioeconomic status and prostate cancer using two-sample Mendelian randomization study by Zhenxing Wang, Chunyan Wang, Xing Gou, Liang Pei, Xiaoyuan Qiao

Subjects: “…Prostate cancer…”
Get full text

Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study by David H Brewster, Victoria Cairnduff, Eila Watson, Amy Downing, Adam W Glaser, Penny Wright, William Cross, Conan Donnelly, Anna Gavin, Carol Rivas, Richard Wagland, Peter Selby, Luke Hounsome, Therese Kearney, Rebecca Mottram, Majorie Allen, Oonagh McSorley, Hugh Butcher, Paul Kind, James W H Catto, Dyfed Huws, Emma McNair, Lauren Matheson, Johana Nayoan, Mike Horton, Jessica Corner, Julia Verne

“…The Life After Prostate Cancer Diagnosis (LAPCD) study is a UK-wide patient-reported outcomes study which will generate information to improve the health and well-being of men with prostate cancer.Methods and analysis Postal surveys will be sent to prostate cancer survivors (18–42 months postdiagnosis) in all 4 UK countries (n=∼70 000). …”
Get full text

Co-modulation of a circular form of PCDH11Y during neuroendocrine differentiation of prostate cancer by Giovanni Pecoraro, Ilaria Leone, Silvia Nuzzo, Santiago Negueruela, Giovanni Smaldone, Lorena Buono

Subjects: Get full text

The Direct Healthcare Expenditures of Prostate Cancer by Disease Severity: Evidence from US National Survey Data by Peter J. Mallow, Jie Chen, John A. Rizzo, John R. Penrod, Geralyn C. Trudel, Teresa M. Zyczynski

“…**Background:** In the United States, approximately 2.8 million men have a history of prostate cancer (PC). **Objective:** This study quantified the effects of PC, overall and by disease severity on direct healthcare costs to insurers and patients. …”
Get full text

Awareness of prostate cancer and its screening tests in men in the Middle East: A systematic review and meta-analysis by Nawaf S.A. Mohamed, Joud M.O. Asfari, Samar M.A. Sambawa, Rima M.D. Aljurf, Kholoud A.A. Alsaygh, Assad M. Arafah

Subjects: Get full text

The effectiveness of dyadic interventions for health outcomes of prostate cancer patients and informal caregivers: a systematic review and meta-analysis by Yuan Xiao, Jiao Sun, Min Liu, Haifeng Wang, Jingjing Guan

Subjects: “…Prostate cancer…”
Get full text

Prostate cancer screening knowledge and attitude among men over 50 at a referral Hospital in Oshana region, Namibia by Lonia Kashihakumwa, Daniel O. Ashipala, Yahaya Jafaru

“…Background: Prostate cancer is the third most common cancer in men and fourth in causing cancer-related deaths in both men and women in Africa. …”
Get full text

Exploring the multi-targeted mechanism of Saikosaponin A in prostate cancer treatment: a network pharmacology and molecular docking approach by Genbao Zhu, Genbao Zhu, Genbao Zhu, Zhiming Jiang, Niuping Zhu, Niuping Zhu, Donghui Wang, Donghui Wang, Tianpeng Guo, Tianpeng Guo, Yiqing Meng, Yiqing Meng, Yi Zhu, Yi Zhu, Kemeng Tan, Mengxue Hu, Heng Tang, Xuannian Wang, Xuannian Wang

Subjects: Get full text

Optimizing the dose-averaged linear energy transfer for the dominant intraprostatic lesions in high-risk localized prostate cancer patients by Bo Zhao, Nobuyuki Kanematsu, Shuri Aoki, Shinichiro Mori, Hideyuki Mizuno, Takamitsu Masuda, Hideyuki Takei, Hitoshi Ishikawa

Subjects: “…Localized prostate cancer…”
Get full text

Phthalate exposure induces microRNA-5010/Nrf2-EGR1/GDF15 signaling expression in prostate cancer by Yuh-Shyan Tsai, Yeong-Chin Jou, Ian Seng Cheong, Hsiu-Ting Tung, Lin-Nei Hsu, Hsin-Tzu Tsai, Tzong-Shin Tzai

Subjects: Get full text

Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information by Laura E. Marin, Daniel I. Zavaleta-Guzman, Jessyca I. Gutierrez-Garcia, Daniel Racoceanu, Fanny L. Casado

Subjects: “…Prostate cancer…”
Get full text

Editorial: Obesity and cancer: the possible molecular links by Biswarup Basu, Debanjan Chakroborty, Debanjan Chakroborty, Debanjan Chakroborty, Chandrani Sarkar, Chandrani Sarkar, Chandrani Sarkar

Subjects: Get full text

Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain by Eva Tirado Mercier, Daniel Callejo Velasco, Marta Rubio Cabezas, Cristina Moretones Agut, Meritxell Granell Villalón

“…**Purpose:** To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. …”
Get full text

Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy by Matteo Pacini, Alessandro Zucchi, Riccardo Morganti, Filippo Dazzi, Antonio Luigi Pastore, Fabio Maria Valenzi, Andrea Fuschi, Yazan al Salhi, Gianluca Giannarini, Vincenzo Ficarra, Alchiede Simonato, Petar Antonov, Pinuccia Faviana, Riccardo Bartoletti

Subjects: “…Prostate cancer diagnosis…”
Get full text

Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting by Benjamin H. Lowentritt, Carmine Rossi, Erik Muser, Frederic Kinkead, Bronwyn Moore, Patrick Lefebvre, Dominic Pilon, Shawn Du

“…**Background:** The use of androgen receptor signaling inhibitors, including apalutamide, in combination with androgen deprivation therapy is recommended for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). …”
Get full text

Major adverse cardiovascular events among Black and White Veterans receiving androgen deprivation therapy for prostate cancer: a retrospective cohort study by Alexander R. Lucas, Dustin Bastiach, Bassam Dahman, Asit K. Paul, Samina Hirani, Vanessa B. Sheppard, W. Gregory Hundley, Bhaumik B. Patel, Rhonda L. Bitting, Michael G. Chang

Subjects: Get full text

Metastatic gastric adenocarcinoma in prostate: A case report by Naru Shimizu, Bunya Kawamoto, Kuniyasu Muraoka

Subjects: “…Prostate cancer metastasis…”
Get full text

Curcumin inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells via IGF-1/PI3K/Akt pathway by Chao Chen, Qiwu Wang, Jiwen Liu

“…Objective This study aimed to investigate the possible mechanism by which curcumin inhibits human prostate cancer (PCa) and castration-resistant prostate cancer (CRPC). …”
Get full text